AstraZeneca’s Imfinzi combination with chemo approved in EU to treat NSCLC
Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...
Pharmabiz1d
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
Zacks Investment Research on MSN4d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...
Fierce Pharma5d
AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...
PipelineReview.com2d
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
PMLive5d
AstraZeneca’s Imfinzi regimen approved by FDA to treat muscle-invasive bladder cancer
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...
AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo
AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential ...
AstraZeneca’s Imfinzi approved in US for treatment of adults with MIBC
Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...
AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...
Medical Dialogues2d
AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...
Yahoo Finance5d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...